STENOTROPHOMONAS MALTOPHILIA BLOODSTREAMINFECTION IN CHILDREN WITH HEMATOLOGIC DISEASES
(Abstract release date: 05/19/16)
EHA Library. Albayrak C. 06/09/16; 135072; PB2172
Prof. Dr. Canan Albayrak
Contributions
Contributions
Abstract
Abstract: PB2172
Type: Publication Only
Background
Stenotrophomonas maltophilia (S. maltophilia) causes serious infections in immunocompromised hosts which early use of susceptible antibacterial may be lifesaving.
Aims
We investigated the clinical characteristics of S. maltophilia bloodstream infection (BSI) in children with hematologic diseases.
Methods
We retrospectively reviewed the medical and microbiological records of all consecutive episodes of S. maltophilia BSIs in children with hematologic diseases and hematopoietic Stem Cell Transplantation (HCT) recipients at the University Hospital (Samsun, Turkey) between January 2006 and January 2016.
Results
Among 762 patients identified as S. maltophilia BSIs during 10-year period, 26 children were identified as hematologic diseases; 7 ALL, 3 AML, 2 Fanconi anemia, 5 aquired aplastic anemia, 2 Diamonnd Blackfan anemia, 1 Griscelli syndrome, 1 Diskerotozis Congenita, 1 Ataksia telengiektasia, 1 JMML, 1 MPS type I, 1 Hereditery spherocytosis and splenectomy, 1 JRA and macrophage activation syndrome. Fifteen of them were HCT recipients. Other eleven of them have been treated with immunesupresive drugs. Fifteen (58%) patients were female. The median patient age was 8.6 years (range: 0.6–18 years). Five patient have cutaneous infection (ecthyma gangrenosum). In vitro susceptibilities to trimethoprim-sulfamethoxazole (TMP-SXT) were 100%.
Conclusion
S. maltophilia BSIs may cause to sepsis, especially in patient with severe neutropenia, shock, and pneumonia. It should be in mind when fever, sepsis and ecthyma gangrenosum finding continued although the use of standard antibiotics of febril neutropenia. TMZ-SXT should be first treatment choice for S. maltophilia BSIs in hematologic patients based upon drug susceptibility testing.
Session topic: E-poster
Keyword(s): Bone marrow transplant, Infection, Malignancy, Supportive care
Type: Publication Only
Background
Stenotrophomonas maltophilia (S. maltophilia) causes serious infections in immunocompromised hosts which early use of susceptible antibacterial may be lifesaving.
Aims
We investigated the clinical characteristics of S. maltophilia bloodstream infection (BSI) in children with hematologic diseases.
Methods
We retrospectively reviewed the medical and microbiological records of all consecutive episodes of S. maltophilia BSIs in children with hematologic diseases and hematopoietic Stem Cell Transplantation (HCT) recipients at the University Hospital (Samsun, Turkey) between January 2006 and January 2016.
Results
Among 762 patients identified as S. maltophilia BSIs during 10-year period, 26 children were identified as hematologic diseases; 7 ALL, 3 AML, 2 Fanconi anemia, 5 aquired aplastic anemia, 2 Diamonnd Blackfan anemia, 1 Griscelli syndrome, 1 Diskerotozis Congenita, 1 Ataksia telengiektasia, 1 JMML, 1 MPS type I, 1 Hereditery spherocytosis and splenectomy, 1 JRA and macrophage activation syndrome. Fifteen of them were HCT recipients. Other eleven of them have been treated with immunesupresive drugs. Fifteen (58%) patients were female. The median patient age was 8.6 years (range: 0.6–18 years). Five patient have cutaneous infection (ecthyma gangrenosum). In vitro susceptibilities to trimethoprim-sulfamethoxazole (TMP-SXT) were 100%.
Conclusion
S. maltophilia BSIs may cause to sepsis, especially in patient with severe neutropenia, shock, and pneumonia. It should be in mind when fever, sepsis and ecthyma gangrenosum finding continued although the use of standard antibiotics of febril neutropenia. TMZ-SXT should be first treatment choice for S. maltophilia BSIs in hematologic patients based upon drug susceptibility testing.
Session topic: E-poster
Keyword(s): Bone marrow transplant, Infection, Malignancy, Supportive care
Abstract: PB2172
Type: Publication Only
Background
Stenotrophomonas maltophilia (S. maltophilia) causes serious infections in immunocompromised hosts which early use of susceptible antibacterial may be lifesaving.
Aims
We investigated the clinical characteristics of S. maltophilia bloodstream infection (BSI) in children with hematologic diseases.
Methods
We retrospectively reviewed the medical and microbiological records of all consecutive episodes of S. maltophilia BSIs in children with hematologic diseases and hematopoietic Stem Cell Transplantation (HCT) recipients at the University Hospital (Samsun, Turkey) between January 2006 and January 2016.
Results
Among 762 patients identified as S. maltophilia BSIs during 10-year period, 26 children were identified as hematologic diseases; 7 ALL, 3 AML, 2 Fanconi anemia, 5 aquired aplastic anemia, 2 Diamonnd Blackfan anemia, 1 Griscelli syndrome, 1 Diskerotozis Congenita, 1 Ataksia telengiektasia, 1 JMML, 1 MPS type I, 1 Hereditery spherocytosis and splenectomy, 1 JRA and macrophage activation syndrome. Fifteen of them were HCT recipients. Other eleven of them have been treated with immunesupresive drugs. Fifteen (58%) patients were female. The median patient age was 8.6 years (range: 0.6–18 years). Five patient have cutaneous infection (ecthyma gangrenosum). In vitro susceptibilities to trimethoprim-sulfamethoxazole (TMP-SXT) were 100%.
Conclusion
S. maltophilia BSIs may cause to sepsis, especially in patient with severe neutropenia, shock, and pneumonia. It should be in mind when fever, sepsis and ecthyma gangrenosum finding continued although the use of standard antibiotics of febril neutropenia. TMZ-SXT should be first treatment choice for S. maltophilia BSIs in hematologic patients based upon drug susceptibility testing.
Session topic: E-poster
Keyword(s): Bone marrow transplant, Infection, Malignancy, Supportive care
Type: Publication Only
Background
Stenotrophomonas maltophilia (S. maltophilia) causes serious infections in immunocompromised hosts which early use of susceptible antibacterial may be lifesaving.
Aims
We investigated the clinical characteristics of S. maltophilia bloodstream infection (BSI) in children with hematologic diseases.
Methods
We retrospectively reviewed the medical and microbiological records of all consecutive episodes of S. maltophilia BSIs in children with hematologic diseases and hematopoietic Stem Cell Transplantation (HCT) recipients at the University Hospital (Samsun, Turkey) between January 2006 and January 2016.
Results
Among 762 patients identified as S. maltophilia BSIs during 10-year period, 26 children were identified as hematologic diseases; 7 ALL, 3 AML, 2 Fanconi anemia, 5 aquired aplastic anemia, 2 Diamonnd Blackfan anemia, 1 Griscelli syndrome, 1 Diskerotozis Congenita, 1 Ataksia telengiektasia, 1 JMML, 1 MPS type I, 1 Hereditery spherocytosis and splenectomy, 1 JRA and macrophage activation syndrome. Fifteen of them were HCT recipients. Other eleven of them have been treated with immunesupresive drugs. Fifteen (58%) patients were female. The median patient age was 8.6 years (range: 0.6–18 years). Five patient have cutaneous infection (ecthyma gangrenosum). In vitro susceptibilities to trimethoprim-sulfamethoxazole (TMP-SXT) were 100%.
Conclusion
S. maltophilia BSIs may cause to sepsis, especially in patient with severe neutropenia, shock, and pneumonia. It should be in mind when fever, sepsis and ecthyma gangrenosum finding continued although the use of standard antibiotics of febril neutropenia. TMZ-SXT should be first treatment choice for S. maltophilia BSIs in hematologic patients based upon drug susceptibility testing.
Session topic: E-poster
Keyword(s): Bone marrow transplant, Infection, Malignancy, Supportive care
{{ help_message }}
{{filter}}